Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Novel CAR T, Anti-PD-1 Combo Shows Promise in MPD
Key clinical point: A novel combined chimeric antigen receptor T-cell/anti–programmed death 1 therapy shows promise in malignant pleural disease.
Major finding: Two patients had a complete metabolic response at 38 and 60 weeks following checkpoint blockade, 5 had a partial response, and 4 had stable disease.
Study details: A phase 1 clinical trial involving 21 patients.
Disclosures: Dr. Adusumilli reported receiving federal grant support from the National Cancer Institute and Department of Defense; peer-reviewed grant support from the Mesothelioma Applied Research Foundation, Experimental Therapeutics Center, Baker Street Foundation, Batishwa Fellowship, Dallepezze Foundation, Derfner Foundation, Emerson Collective Foundation, and MSK Technology Development Fund; and research grant support from OSE Immunotherapeutics, ACEA Biosciences, and Atara Biotherapeutics. He also has a licensing/royalty agreement for Mesothelin CAR and PD-1 DNR (licensed to Atara Biotherapeutics).
Adusumilli PS et al. AACR 2019, Abstract CT036.